Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2 publications
Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment.
Journal: Oncotarget
Published: January 04, 2017
Immunotargeting and eradication of orthotopic melanoma using a chemokine-enhanced DNA vaccine.
Journal: Gene therapy
Published: September 19, 2012
Showing 1-2 of 2
Last Updated: 09/26/2026